Market closed
Trevi Therapeutics/TRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
TRVI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
26
Website
TRVI Metrics
BasicAdvanced
$226M
Market cap
-
P/E ratio
-$0.39
EPS
0.97
Beta
-
Dividend rate
Price and volume
Market cap
$226M
Beta
0.97
52-week high
$4.00
52-week low
$0.97
Average daily volume
387K
Financial strength
Current ratio
10.683
Quick ratio
10.293
Long term debt to equity
1.336
Total debt to equity
1.803
Interest coverage (TTM)
-4,797.00%
Management effectiveness
Return on assets (TTM)
-30.88%
Return on equity (TTM)
-48.09%
Valuation
Price to book
3.42
Price to tangible book (TTM)
3.42
Price to free cash flow (TTM)
-9.481
Growth
Earnings per share change (TTM)
28.46%
3-year earnings per share growth (CAGR)
-40.49%
What the Analysts think about TRVI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
TRVI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TRVI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TRVI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $226M as of October 13, 2024.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of October 13, 2024.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of October 13, 2024.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.